These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 36430692)

  • 1. Impact of Siponimod on Enteric and Central Nervous System Pathology in Late-Stage Experimental Autoimmune Encephalomyelitis.
    Weier A; Enders M; Kirchner P; Ekici A; Bigaud M; Kapitza C; Wörl J; Kuerten S
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Siponimod treatment response shows partial BDNF dependency in multiple sclerosis models.
    Hendek HH; Blusch A; Heitmann N; Oberhagemann S; Demir S; Pedreiturria X; Gold R; Faissner S
    Sci Rep; 2024 Aug; 14(1):17823. PubMed ID: 39090252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Morpholino Analogues of Fingolimod as Novel and Selective S1P
    Stepanovska B; Zivkovic A; Enzmann G; Tietz S; Homann T; Kleuser B; Engelhardt B; Stark H; Huwiler A
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32899717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Siponimod (BAF312) prevents synaptic neurodegeneration in experimental multiple sclerosis.
    Gentile A; Musella A; Bullitta S; Fresegna D; De Vito F; Fantozzi R; Piras E; Gargano F; Borsellino G; Battistini L; Schubart A; Mandolesi G; Centonze D
    J Neuroinflammation; 2016 Aug; 13(1):207. PubMed ID: 27566665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Central Versus Peripheral Drug Exposure Ratio, a Key Differentiator for Siponimod Over Fingolimod?
    Bigaud M; Ramseier P; Tisserand S; Lang M; Urban B; Beerli C; Karlsson G
    Neurol Ther; 2023 Aug; 12(4):1187-1203. PubMed ID: 37195409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does Siponimod Exert Direct Effects in the Central Nervous System?
    Kipp M
    Cells; 2020 Jul; 9(8):. PubMed ID: 32722245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Indirect comparisons of siponimod with fingolimod and ofatumumab in multiple sclerosis: assessing the feasibility of propensity score matching analyses.
    Samjoo IA; Worthington E; Haltner A; Spin P; Drudge C; Cameron C; Brennan R; Dahlke F; Adlard N
    Curr Med Res Opin; 2021 Nov; 37(11):1933-1944. PubMed ID: 34384311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Benefits and Risks of Switching from Fingolimod to Siponimod for the Treatment of Relapsing-Remitting and Secondary Progressive Multiple Sclerosis.
    Vališ M; Achiron A; Hartung HP; Mareš J; Tichá V; Štourač P; Halusková S; Angelucci F; Pavelek Z
    Drugs R D; 2023 Dec; 23(4):331-338. PubMed ID: 37640862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Siponimod ameliorates metabolic oligodendrocyte injury via the sphingosine-1 phosphate receptor 5.
    Behrangi N; Heinig L; Frintrop L; Santrau E; Kurth J; Krause B; Atanasova D; Clarner T; Fragoulis A; Joksch M; Rudolf H; Meuth SG; Joost S; Kipp M
    Proc Natl Acad Sci U S A; 2022 Oct; 119(40):e2204509119. PubMed ID: 36161894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Re-emergence of T lymphocyte-mediated synaptopathy in progressive multiple sclerosis.
    Sanna K; Bruno A; Balletta S; Caioli S; Nencini M; Fresegna D; Guadalupi L; Dolcetti E; Azzolini F; Buttari F; Fantozzi R; Borrelli A; Stampanoni Bassi M; Gilio L; Lauritano G; Vanni V; De Vito F; Tartacca A; Mariani F; Rovella V; Musella A; Centonze D; Mandolesi G
    Front Immunol; 2024; 15():1416133. PubMed ID: 38911847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Siponimod: a new view at the therapy of secondary progressive multiple sclerosis].
    Krasnov VS; Kolontareva YM
    Zh Nevrol Psikhiatr Im S S Korsakova; 2021; 121(7):124-129. PubMed ID: 34460168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sphingosine-1-Phosphate (S1P) and S1P Signaling Pathway Modulators, from Current Insights to Future Perspectives.
    Bravo GÁ; Cedeño RR; Casadevall MP; Ramió-Torrentà L
    Cells; 2022 Jun; 11(13):. PubMed ID: 35805142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. S1P receptor antagonists fingolimod and siponimod do not improve the outcome of experimental autoimmune myasthenia gravis mice after disease onset.
    Pelz A; Schaffert H; Diallo R; Hiepe F; Meisel A; Kohler S
    Eur J Immunol; 2018 Mar; 48(3):498-508. PubMed ID: 29205338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Siponimod Attenuates Neuronal Cell Death Triggered by Neuroinflammation via NFκB and Mitochondrial Pathways.
    Gurrea-Rubio M; Wang Q; Mills EA; Wu Q; Pitt D; Tsou PS; Fox DA; Mao-Draayer Y
    Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sphingosine 1-phosphate receptor modulation suppresses pathogenic astrocyte activation and chronic progressive CNS inflammation.
    Rothhammer V; Kenison JE; Tjon E; Takenaka MC; de Lima KA; Borucki DM; Chao CC; Wilz A; Blain M; Healy L; Antel J; Quintana FJ
    Proc Natl Acad Sci U S A; 2017 Feb; 114(8):2012-2017. PubMed ID: 28167760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Siponimod Inhibits the Formation of Meningeal Ectopic Lymphoid Tissue in Experimental Autoimmune Encephalomyelitis.
    Brand RM; Diddens J; Friedrich V; Pfaller M; Radbruch H; Hemmer B; Steiger K; Lehmann-Horn K
    Neurol Neuroimmunol Neuroinflamm; 2022 Jan; 9(1):. PubMed ID: 34911793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy.
    Groves A; Kihara Y; Chun J
    J Neurol Sci; 2013 May; 328(1-2):9-18. PubMed ID: 23518370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis.
    Cohen JA; Chun J
    Ann Neurol; 2011 May; 69(5):759-77. PubMed ID: 21520239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. S1P(1) receptor modulation with cyclical recovery from lymphopenia ameliorates mouse model of multiple sclerosis.
    Gonzalez-Cabrera PJ; Cahalan SM; Nguyen N; Sarkisyan G; Leaf NB; Cameron MD; Kago T; Rosen H
    Mol Pharmacol; 2012 Feb; 81(2):166-74. PubMed ID: 22031473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spotlight on siponimod and its potential in the treatment of secondary progressive multiple sclerosis: the evidence to date.
    Gajofatto A
    Drug Des Devel Ther; 2017; 11():3153-3157. PubMed ID: 29138536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.